Non-Cystic Fibrosis Bronchiectasis (NCFB) Pipeline Summary

DelveInsight’s, “Non-Cystic Fibrosis Bronchiectasis (NCFB) - Pipeline Insight, 2026” report provides comprehensive insights about 13+ companies and 15+ pipeline drugs in Non-Cystic Fibrosis Bronchiectasis (NCFB) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Non-Cystic Fibrosis Bronchiectasis (NCFB): Understanding

Non-Cystic Fibrosis Bronchiectasis (NCFB): Overview

Non–cystic fibrosis (non-CF) bronchiectasis (henceforth referred to as bronchiectasis) is a progressive respiratory disease characterized by a permanent dilation of bronchi, retention of mucus, and ciliary clearance impairment. Clinical features include chronic daily sputum, cough, shortness of breath, and recurrent respiratory infections, with consequent increased morbidity and worsened quality of life. One of the cornerstones in the management of bronchiectasis is the identification and treatment of underlying causes.

Non-cystic fibrosis bronchiectasis (NCFB) presents with variable symptoms ranging from asymptomatic periods to daily manifestations. Common symptoms include chronic cough with mucopurulent sputum production, dyspnea, wheezing, and pleuritic chest pain. Physical examination may reveal adventitious breath sounds like crackles, wheezing, or rhonchi. Exacerbations, marked by changes in sputum production, dyspnea, cough, fever, wheezing, and decreased exercise tolerance, are frequent and define disease progression. Monitoring for symptoms and exacerbation triggers is crucial for managing NCFB effectively.

Non-cystic fibrosis bronchiectasis (NCFB) is characterized by irreversible widening and thickening of the medium-sized airways, accompanied by chronic inflammation and bacterial infection. The pathological process involves a vicious cycle of excessive bronchial inflammation, bacterial colonization, and recurrent infections, leading to progressive destruction of the bronchial walls. NCFB can present in different radiographic patterns, including cylindrical (dilated airways), varicose (focal constrictions), and saccular/cystic (large cyst-like dilations).

The increased recognition of NCFB is likely a result of the use of high?resolution computed tomography (HRCT), which has allowed for the identification of previously undiagnosed disease. HRCT, which is able to acquire 1?mm thick images of the lung at 10?mm intervals, is considered the gold standard for radiographic diagnosis of NCFB. Other modalities of CT using different imaging algorithms have been frequently used to effectively diagnose bronchiectasis.

The treatment of bronchiectasis focuses on managing symptoms, slowing decline in lung function and preventing exacerbations. Patients should be encouraged to take general changes that will make a large difference such as smoking cessation. Chest physiotherapy is a well-established treatment with little in the way of side effects. Some patients may respond to more specialist treatments such as regular antibiotics, often in the form of a low dose macrolide three times a week. Frailty and co-morbidities play a role in deciding on the appropriateness of these treatments.

"Non-Cystic Fibrosis Bronchiectasis (NCFB) - Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Non-Cystic Fibrosis Bronchiectasis (NCFB) pipeline landscape is provided which includes the disease overview and Non-Cystic Fibrosis Bronchiectasis (NCFB) treatment guidelines. The assessment part of the report embraces, in depth Non-Cystic Fibrosis Bronchiectasis (NCFB) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Non-Cystic Fibrosis Bronchiectasis (NCFB) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Non-Cystic Fibrosis Bronchiectasis (NCFB) R&D. The therapies under development are focused on novel approaches to treat/improve Non-Cystic Fibrosis Bronchiectasis (NCFB).

Non-Cystic Fibrosis Bronchiectasis (NCFB) Emerging Drugs Chapters

This segment of the Non-Cystic Fibrosis Bronchiectasis (NCFB) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Non-Cystic Fibrosis Bronchiectasis (NCFB) Emerging Drugs

• HSK31858/ CHF10196: CHIESI USA, Inc./Haisco Pharmaceutical Group Co., Ltd.

HSK31858 (CHF10196) is an investigational oral phosphodiesterase-4 (PDE4) inhibitor being co-developed by Chiesi USA, Inc. and Haisco Pharmaceutical Group Co., Ltd. for the treatment of non-cystic fibrosis bronchiectasis (NCFB). The drug is designed to reduce chronic airway inflammation by selectively inhibiting the PDE4 enzyme, thereby increasing intracellular cyclic adenosine monophosphate (cAMP) levels in inflammatory cells. Its mechanism of action (MOA) suppresses the production of pro-inflammatory cytokines and limits the activation and recruitment of neutrophils, helping to reduce airway inflammation, improve lung function, and decrease the frequency of pulmonary exacerbations in patients with NCFB. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Non-Cystic Fibrosis Bronchiectasis (NCFB).

• CSL787: CSL Behring

CSL787 is an investigational human plasma-derived immunoglobulin (IgG) inhalation solution, administered via a nebulizer, the drug is designed to deliver immunoglobulin directly to the lungs, with the aim of preventing chronic respiratory tract infections and slowing the progression of chronic lung disease in patients with NCFB. By enhancing local immune defense within the airways, the therapy seeks to reduce recurrent pulmonary exacerbations and improve respiratory health in individuals with impaired airway host defense. Currently, The drug is in Phase II stage of its development for non-cystic fibrosis bronchiectasis(NCFB).

Further product details are provided in the report……..

Non-Cystic Fibrosis Bronchiectasis (NCFB) : Therapeutic Assessment

This segment of the report provides insights about the different Non-Cystic Fibrosis Bronchiectasis (NCFB) drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Non-Cystic Fibrosis Bronchiectasis (NCFB)

There are approx. 13+ key companies which are developing the therapies Non-Cystic Fibrosis Bronchiectasis (NCFB) . The companies which have their Non-Cystic Fibrosis Bronchiectasis (NCFB) drug candidates in the most advanced stage, i.e. Phase III include, CHIESI USA, Inc., Haisco Pharmaceutical Group Co., Ltd., and others.

• Phases

DelveInsight’s report covers around 15+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Non-Cystic Fibrosis Bronchiectasis (NCFB) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Non-Cystic Fibrosis Bronchiectasis (NCFB) : Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Non-Cystic Fibrosis Bronchiectasis (NCFB) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Non-Cystic Fibrosis Bronchiectasis (NCFB) drugs.

Non-Cystic Fibrosis Bronchiectasis (NCFB) Report Insights

• Non-Cystic Fibrosis Bronchiectasis (NCFB) Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Non-Cystic Fibrosis Bronchiectasis (NCFB) Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Non-Cystic Fibrosis Bronchiectasis (NCFB) drugs?
• How many Non-Cystic Fibrosis Bronchiectasis (NCFB) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Non-Cystic Fibrosis Bronchiectasis (NCFB)?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Non-Cystic Fibrosis Bronchiectasis (NCFB) therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Non-Cystic Fibrosis Bronchiectasis (NCFB) and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• CHIESI USA, Inc.
• Haisco Pharmaceutical Group Co., Ltd.
• CSL Behring
• Sanofi
• AATec Medical
• Thirty Respiratory

Key Products

• HSK31858/ CHF10196
• CSL 787
• SAR445399
• ATL 105
• RESP302